All In Biotech

Drug Trial Radar · NCT04281342

To Study the Effect of Aprocitentan on the Electrical Activity of the Heart in Healthy Men and Women

Prospective, Single-center, Randomized, Double-blind, Placebo- and Moxifloxacin-controlled, 4-way Crossover Phase 1 Study to Assess the Effect of Multiple Therapeutic and Supratherapeutic Doses of Aprocitentan on the QT Interval Duration in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Nov 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Jan 14, 2020

Primary completion

Aug 3, 2021

Study completion Sep 3, 2021

Sponsor

Lead sponsor
Idorsia Pharmaceuticals Ltd.Industry
Sponsor type
Industry
First posted
Feb 24, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To demonstrate that multiple-dose administration of oral therapeutic and supratherapeutic doses of aprocitentan do not have a clinically relevant effect on the QT interval.

Conditions

  • Healthy Subjects

Interventions

  • Aprocitentan 25 mgDrug

    Repeated administration of a 25 mg oral dose of aprocitentan, once daily from Day 1 to Day 10, followed by 18 days of observation.

  • Aprocitentan 100 mgDrug

    Repeated administration of a 100 mg oral dose of aprocitentan, once daily from Day 1 to Day 10, followed by 18 days of observation.

  • Matching placeboDrug

    Repeated administration of an oral dose of aprocitentan-matching placebo, once daily from Day 1 to Day 10, followed by 18 days of observation.

  • Moxifloxacin control to establish assay sensitivityOther

    Repeated administration of an oral dose of aprocitentan-matching placebo, once daily from Day 1 to Day 9. On Day 10, oral administration of one single 400 mg moxifloxacin tablet open-label, followed by 18 days of observation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Placebo-corrected change from baseline in QT interval corrected with Fridericia's formula (ΔΔQTcF)Time frame: Multiple predefined time points related to study treatment administration on Day 1 and Day 10 to 11 of each treatment.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CRS Clinical Research Services Mannheim GmbH

    Mannheim, Baden-Wurttemberg, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.